Puration Inc Cannabis Beverage Appeal Refreshed with Anheuser Busch and Tilray Deal
December 26 2018 - 10:48AM
InvestorsHub NewsWire
Puration Inc Cannabis Beverage
Appeal Refreshed with Anheuser Busch and Tilray Deal
Dallas, TX -- December 26, 2018 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) (“PURA”) today reemphasized the company’s cannabis
beverage industry experience and direction in light of the recently
announced Anheuser Busch Inbev NV (NYSE:BUD) and
Tilray Inc. (NASDAQ:TLRY) cannabis-infused
beverage deal with both firms investing $50 million each to
research potential beverage production. “Cannabis infused beverage
industry interest heated up last year around Canada’s legalization
of recreational marijuana,” said Brian Shibley, CEO of Puration.
“Among other notable fortune 500 beverage industry announcements
regarding interest in the cannabis beverage market, Puration got
its tires kicked by a heavy weight. Now with the US
legalization of hemp farming, big beverage industry players are
renewing their interest. While the big players invest money
to explore potential cannabis infused beverage industry production,
Puration has $1 million in cannabis infused beverage sales under
its belt and has set a goal on ringing $5 million in sales next
year. By the way, we’ve already experimented with hemp beer.
I thought I’d mention that today in light of the Anheuser Busch
announcement.” Puration recently released a 2018 year-end
report detailing the company’s historical sales and 2019 sales
goals. The report also includes new information on previously
announced plans to issue a dividend of Nouveau Life
Pharmaceuticals, (USOTC:
NOUV) (“NOUV”) stock to PURA shareholders that will speed up
the issuance in addition to, management believes, improving the
overall value of the dividend. Management also includes in
the update highlights of business developments with US Cannabis
Health partners NOUV and Kali-Extracts (USOTC:
KALY). See the report on the company’s website at
https://www.purationinc.com/2018-year-end-upate.
To learn more about
Puration, Inc., visit www.purationinc.com.
Disclaimer/Safe
Harbor:
This news
release contains forward-looking statements within the meaning of
the Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that any of the companies mentioned herein will achieve
significant sales, the failure to meet schedule or performance
requirements of the companies' contracts, the companies' liquidity
position, the companies' ability to obtain new contracts, the
emergence of competitors with greater financial resources and the
impact of competitive pricing. In the light of these uncertainties,
the forward-looking events referred to in this release might not
occur. These statements have not been evaluated by the Food and
Drug Administration. These products are not intended to diagnose,
treat, cure, or prevent any disease.
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Apr 2023 to Apr 2024